Trials / Completed
CompletedNCT01033487
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
A Phase 2A, Double Blind, Placebo-Controlled, Single Dose, 5-Way Crossover Study Assessing The Pharmacodynamic, Pharmacokinetic And Safety Profiles Of Oral Inhaled PF-03635659 In Patients With Moderate Chronic Obstructive Pulmonary Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Pulmonary Disease, Chronic Obstructive
- Lung Diseases
- Respiratory Tract Diseases
- Chronic Obstructive Airway Disease
- COPD
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | oral inhaled formulation, single dose |
| DRUG | active comparator | oral inhaled formulation, single dose |
| DRUG | Low Dose PF-03635659 | oral inhaled formulation, single dose, low dose |
| DRUG | Mid Dose PF-03635659 | oral inhaled formulation, single dose, mid dose |
| DRUG | High Dose PF-03635659 | oral inhaled formulation, single dose, high dose |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-12-16
- Last updated
- 2016-02-19
- Results posted
- 2016-02-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01033487. Inclusion in this directory is not an endorsement.